Sera Prognostics

What Sera Prognostics does

Sera Prognostics Inc. (NASDAQ: SERA), headquartered in Salt Lake City, Utah and operating as "The Pregnancy Company," is a publicly traded health diagnostics company founded in 2008 that commercializes blood-based biomarker tests to predict pregnancy complications. Its flagship product, the PreTRM Test, is the first broadly validated, commercially available proteomic blood test that predicts individualized risk of spontaneous preterm birth in asymptomatic singleton pregnancies by measuring IBP4 and SHBG proteins during weeks 18–20 of gestation. The company also operates the LikeMine platform, which draws on data from millions of U.S. pregnancies to provide comparative pregnancy outcome information for expectant mothers.

The business model is centered on one-time laboratory testing fees (CMS-set Medicare rate of $750 for CPT PLA code 0247U) billed through Sera's CLIA-certified, CAP-accredited, and New York State Department of Health-approved laboratory, with test ordering via physicians and processing centralized at the company's lab. The company is pursuing three primary customer segments: healthcare providers (obstetricians and maternal-fetal medicine specialists), government and commercial payers (including a mandate from Illinois Medicaid covering approximately 50,000 Medicaid births annually), and self-insured employers offering advanced maternity benefits. Strategic channel partners include Banner Health, Sonrava Health, Anthem, MultiPlan, and Cerebrae.

Revenue is currently de minimis ($81,000 for full-year 2025 and $14,000 in Q1 2026), reflecting the early commercial stage. The company is investing heavily in payer coverage expansion across 15 states, scaling its sales force, and broadening its product pipeline to include preeclampsia, gestational diabetes, fetal growth restriction, postpartum depression, and a point-of-care fetal hypoxia diagnostic under an ARPA-H award. Following a Q1 2026 strategic realignment shifting capital from R&D to commercialization, the company holds $86.8M in cash (March 31, 2026) with a runway extending through 2029.

Name

Sera Prognostics

Legal name

Sera Prognostics Inc.

Website

https://seraprognostics.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Sera Prognostics (NASDAQ: SERA) is a Salt Lake City-based health diagnostics company that commercializes the PreTRM Test, a blood-based proteomic biomarker test predicting spontaneous preterm birth risk during weeks 18–20 of pregnancy for healthcare providers, payers, and self-insured employers.

Ownership category

akta.pro rank

Product category

Prenatal Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Proteomics & Biomarker Analytical Testing (HLAGADAG), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Prenatal diagnostics
• Preterm birth prediction
• Blood-based biomarker testing
• Maternal health diagnostics
• Proteomic pregnancy testing

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. PreTRM Test Sales: One-time laboratory test revenue from proteomic blood tests sold to healthcare providers for preterm birth risk assessment. Medicare payment rate set at $750 for CPT code 0247U. Currently generating minimal revenue ($14K Q1 2026, $81K full year 2025) as company builds commercial infrastructure and payer coverage.
2. Care Management Services: Associated care management services covered under Medicaid reimbursement frameworks in Illinois and other states pursuing coverage.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Sera Prognostics is a health diagnostics company that develops and commercializes blood-based proteomic biomarker tests to predict pregnancy complications. Its flagship product, the PreTRM Test, is the first broadly validated blood test that provides individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies through a single blood draw at weeks 18-20 of gestation. The company also offers the LikeMine consumer-facing platform that provides personalized pregnancy outcome comparisons, and is building a pipeline of predictive tests for preeclampsia, gestational diabetes, fetal growth restriction, and postpartum depression.

Product overview

Sera Prognostics operates as a health diagnostics company offering a focused portfolio centered on the PreTRM Test as its core commercial product. The PreTRM Test is a blood-based biomarker diagnostic that predicts individual risk of spontaneous preterm birth through proteomic analysis. The company has a secondary offering called LikeMine that provides personalized pregnancy outcome comparisons using aggregated data. The company is also developing a pipeline of tests including preeclampsia, gestational diabetes, fetal growth restriction, and postpartum depression predictors. The business model is centered on laboratory testing services with ongoing payer coverage expansion and Medicaid reimbursement initiatives.

Differentiator

Problem solved

Functional benefit

Brands

• PreTRM: The PreTRM Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
• LikeMine

Products and services

• PreTRM Test The first broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The test measures IBP4 and SHLG proteins through a single blood draw during weeks 18-20 of gestational age, and is for obstetricians, maternal-fetal medicine specialists, and prenatal care providers.
• LikeMine Platform A platform drawing on data from millions of U.S. pregnancies to offer comparisons highlighting what is more common, less common, or similar for women based on their pregnancy profile. Includes a complimentary Complications Summary Report giving expectant mothers an overview of outcomes experienced by women like them.

Quantifiable outcome

• 56% reduction in births before 32 weeks gestation; 32% reduction in births before 35 weeks
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core, strategic and minor.

• UC San DiegocoreStrategic or Co-development Partner · 24 June 2026Multi-institutional research program led by UC San Diego researchers as part of ARPA-H's Making Obstetrics Care Smart (MOCS) initiative. Sera contributing protein biomarker discovery and validation expertise to develop point-of-care diagnostic test for assessing fetal hypoxia risk during labor and delivery using maternal blood samples.
• Allegro MicroSystemscoreTechnology or Integration · 24 June 2026Collaboration as part of $10.4M ARPA-H award to develop rapid testing platform for fetal hypoxia risk assessment. Allegro contributing semiconductor/sensor technology for point-of-care diagnostic development.
• Illinois MedicaidcoreChannel Partner/ Reseller/ DistributorIllinois enacted legislation requiring Medicaid coverage and reimbursement for proteomic blood tests for preterm birth risk, including care management services. Sera's PreTRM Test is the only broadly validated test of its kind covered under this mandate.
• Banner HealthcoreChannel Partner/ Reseller/ DistributorContract signed for Banner's University Family Care/AHCCCS Complete Care Medicaid members serving more than 300,000 members. Banner is an innovative leader in healthcare models providing integrated care.
• Sonrava HealthstrategicChannel Partner/ Reseller/ DistributorNational family of health and wellness companies including Western Dental, providing PreTRM Test to members under employer-sponsored health insurance program through unique platform leveraging actuarial and data science.
• CerebraestrategicGTM or Marketing PartnerInnovator in pricing and measuring financial value of care. Cerebrae's rigorous third-party analysis supported inclusion of PreTRM Test into Sonrava Health maternity benefits plan through platform forecasting financial risk and monitoring performance.
• MultiPlanstrategicChannel Partner/ Reseller/ DistributorContract relationship providing network access for PreTRM Test coverage through MultiPlan's provider network arrangements with payers.
• AnthemstrategicChannel Partner/ Reseller/ DistributorMajor national payer with established coverage relationship for PreTRM Test. Geographic focus in high population density areas where Anthem coverage is concentrated.
• Bill & Melinda Gates Foundation / AMANHIstrategicStrategic or Co-development PartnerInternational study funded by Gates Foundation in collaboration with Alliance for Maternal and Newborn Health Improvement (AMANHI) demonstrating IBP4/SHBG biomarkers predict preterm birth in diverse non-U.S. populations in sub-Saharan Africa and South Asia.
• PreemieWorld, GLOPreemies, Alliance for Black NICU FamiliesminorGTM or Marketing PartnerPatient organization collaborations to empower and support families impacted by preterm birth, providing education about prenatal healthcare and preterm birth risk in underserved communities.
• Society for Maternal-Fetal Medicine (SMFM)strategicGTM or Marketing PartnerProfessional organization engagement for PRIME study data presentation and clinical implementation discussions. Engagement with SMFM leadership on preterm birth risk stratification.
• American College of Obstetricians and Gynecologists (ACOG)strategicGTM or Marketing PartnerParticipation in ACOG Annual Clinical and Scientific Meeting with dedicated product theater and targeted clinician engagement on PreTRM clinical evidence and implementation.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Natera: Natera is a leading cell-free DNA testing company offering NIPT (Panorama) and reproductive health diagnostics. Direct competitor in prenatal screening with similar physician-channel sales motion and comparable regulatory/reimbursement profile.
• Myriad Genetics: Myriad offers Foresight Carrier Screen and Prequel NIPT in prenatal/reproductive health. Direct competitor in women's health genetic diagnostics with established OB channel and shared payer reimbursement infrastructure.
• Invitae (now GeneDx): Invitae/GeneDx offers reproductive and pregnancy-related genetic screening. Direct peer in reproductive health diagnostics with comparable patient/physician journey and reimbursement dynamics.
• Eurofins NTD: Eurofins NTD (NTD Labs) is a specialty prenatal and reproductive diagnostics laboratory. Direct competitor offering maternal serum screening, NIPT, and carrier screening to the same maternal-fetal medicine audience.

Emerging players

• BillionToOne: BillionToOne is a high-growth molecular diagnostics company with UNITY Fetal RhD and NIPT, plus oncology liquid biopsy. Comparable as an emerging single-gestational-age precision diagnostics player targeting similar OB/GYN prescribing physicians.
• Progenity / BioMar Analytics: BioMar Analytics (formed from Progenity assets) and adjacent specialty prenatal labs target similar proteomic and molecular approaches to pregnancy risk prediction. Comparable as an emerging player in precision prenatal diagnostics.

Broad incumbents

• Quest Diagnostics: Quest is a national clinical laboratory offering QNatal NIPT and broad maternal serum screening. Functions as a broad incumbent that competes on the same physician-ordering workflow and may offer alternative preterm risk scoring algorithms.
• Laboratory Corporation of America (LabCorp): LabCorp is a major U.S. clinical lab and historical Sera investor, offering MaterniT21 NIPT and integrated prenatal screening. Broad incumbent peer with overlapping physician customers and competing reproductive health menu.
• Hologic: Hologic's Diagnostic Solutions segment provides women's health cytology and molecular diagnostics. Comparable as a women's health specialty diagnostics incumbent with similar OB/GYN call point and clinical evidence-driven marketing.
• PerkinElmer (Revvity): Revvity (formerly PerkinElmer) provides Vanadis NIPT and reproductive health diagnostics. Broad incumbent with similar clinical lab infrastructure and global footprint in maternal-fetal screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/SeraPrognostics
• LinkedInlinkedin.com/company/sera-prognostics
• Instagraminstagram.com/serathepregnancycompany

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds12 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sera Prognostics